Drugs / Me-CCNU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06673459 | Dec 2024 → Nov 2029 expected | T-cell leukemia | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 0 | NCT05528354 Background | Jun 2022 → Dec 2025 | disease related to hematopoietic stem cell transplant | Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT04688021 Background | Dec 2020 → Dec 2024 | graft versus host disease, leukemia | Yi Luo | Unknown | No outcome recorded |
| Phase 3 | NCT04547049 Comparator | Sep 2020 → Apr 2026 overdue | leukemia, myelodysplastic syndrome | First Affiliated Hospital of Zhejiang University | Active not recruiting | No outcome recorded |
| — | NCT07183878 Background | Aug 2025 → Aug 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05814731 Background | Apr 2023 → Dec 2025 | disease related to hematopoietic stem cell transplant | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Me-CCNU | “The TBI-Cy group was administered 250 mg/m2/d oral Me-CCNU on day -8.” NCT06673459 ↗5“MeCCNU (250 mg/m²/day, day -1)” NCT07183878 ↗ “me-CCNU 250 mg/m2，p.o，d-3” NCT05814731 ↗ “Meccnu 250mg/m2 d-3” NCT05528354 ↗ |
| Route | Oral | “administered orally” NCT04547049 ↗ |